Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: September 30, 2022 Report Code: GDGMDHC22312IDB-ST

Select Item

Parkinsons Disease Pipeline Drugs Market Overview

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under development for Parkinson’s disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson’s disease and features dormant and discontinued projects.

Parkinson’s Disease Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Parkinson’s disease pipeline drugs market are Alpha Synuclein, D2 Dopamine Receptor, D1A Dopamine Receptor, D3 Dopamine Receptor, Leucine Rich Repeat Serine/Threonine Protein Kinase 2, D4 Dopamine Receptor, and Glucosylceramidase.

Parkinson’s Disease Pipeline Drugs Market Analysis, by Targets

Parkinson’s Disease Pipeline Drugs Market Analysis, by TargetsFor more Parkinson’s disease pipeline drugs market target insights, download a free report sample

Parkinson’s Disease Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the mechanisms of action of the Parkinson’s disease pipeline drugs market are Alpha Synuclein Inhibitor, D2 Dopamine Receptor Agonist, D1A Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Inhibitor, and D4 Dopamine Receptor Agonist.

Parkinson’s Disease Pipeline Drugs Market Analysis, by Mechanisms of Action

Parkinson’s Disease Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanism of action insights into the Parkinson’s disease pipeline drugs market, download a free report sample

Parkinson’s Disease Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Parkinson’s disease pipeline drugs market are oral, intravenous, subcutaneous, parenteral, transdermal, nasal, intramuscular, and intrathecal.

Parkinson’s Disease Pipeline Drugs Market Analysis, by Routes of Administration

Parkinson’s Disease Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Parkinson’s disease pipeline drugs market, download a free report sample

Parkinson’s Disease Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Parkinson’s disease pipeline drugs market are Small Molecule, Cell Therapy, Gene Therapy, Monoclonal Antibody, Synthetic Peptide, Biologic, and Recombinant Protein.

Parkinson’s disease Pipeline Drugs Market Analysis, by Molecule Types

Parkinson’s disease Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Parkinson’s disease pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Parkinson’s disease pipeline drugs market are Denali Therapeutics Inc, Bial – Portela & Ca SA, Forest Hills Partners Hong Kong Ltd, Luye Pharma Group Ltd, AstraZeneca Plc, Cerevance Inc, and MD Healthcare Inc.

Parkinson’s Disease Pipeline Drugs Market Analysis, by Companies

Parkinson’s Disease Pipeline Drugs Market Analysis, by Companies

To know more about the Parkinson’s disease pipeline drugs market companies, download a free report sample

Parkinson’s Disease Pipeline Drugs Market Report Overview

Key Targets Alpha Synuclein, D2 Dopamine Receptor, D1A Dopamine Receptor, D3 Dopamine Receptor, Leucine Rich Repeat Serine/Threonine Protein Kinase 2, D4 Dopamine Receptor, and Glucosylceramidase
Key Mechanism of Actions Alpha Synuclein Inhibitor, D2 Dopamine Receptor Agonist, D1A Dopamine Receptor Agonist, D3 Dopamine Receptor Agonist, Leucine Rich Repeat Serine/Threonine Protein Kinase 2 Inhibitor, and D4 Dopamine Receptor Agonist
Key Routes of Administration Oral, Intravenous, Subcutaneous, Parenteral, Transdermal, Nasal, Intramuscular, and Intrathecal
Key Molecule Types Small Molecule, Cell Therapy, Gene Therapy, Monoclonal Antibody, Synthetic Peptide, Biologic, and Recombinant Protein
Key Companies Denali Therapeutics Inc, Bial – Portela & Ca SA, Forest Hills Partners Hong Kong Ltd, Luye Pharma Group Ltd, AstraZeneca Plc, Cerevance Inc, and MD Healthcare Inc.

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Parkinson’s disease.
  • Reviews of pipeline therapeutics for Parkinson’s disease by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews key companies involved in Parkinson’s disease therapeutics and enlists all their major and minor projects.
  • Evaluation of Parkinson’s disease therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Parkinson’s disease.

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Parkinson’s disease.

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Parkinson’s disease pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

1st Bio Therapeutics Inc
2N Pharma ApS
3Z ehf
4D Pharma Plc
Abaxy Sprl
Abaxys Therapeutics SA
AbbVie Inc
Abfero Pharmaceuticals Inc
Abivax SA
ABL Bio Inc
AC Immune SA
Accure Therapeutics SL
AceLink Therapeutics Inc
Acelot Inc
AcureX Therapeutics Corp
Addex Therapeutics Ltd
Adhera Therapeutics Inc
Adicet Bio Inc
Aeterna Zentaris Inc
AevisBio Inc
AgoneX Biopharmaceuticals Inc
Akome Biotech Ltd
Alan Laboratories Inc
Alar Pharmaceuticals Inc
Alector Inc
Alexza Pharmaceuticals Inc
Alkahest Inc
AlphaCognition Inc
Alsonex Pty Ltd
Alterity Therapeutics Ltd
AltPep Corp
AlzeCure Pharma AB
Amathus Therapeutics Inc
Amneal Pharmaceuticals Inc
Anavex Life Sciences Corp
ANLBio Co Ltd
Annovis Bio Inc
Aoxing Pharmaceutical Company Inc
Appello Pharmaceuticals Inc
Aprinoia Therapeutics Inc
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Aranda Pharma Ltd
AriBio
ArmaGen Inc
Arrien Pharmaceuticals LLC
Artizan Biosciences Inc
ArunA Bio Inc
Arvinas Inc
Asceneuron SA
Asdera LLC
Asha Therapeutics LLC
Ashvattha Therapeutics LLC
Asklepios BioPharmaceutical Inc
Aspen Neuroscience Inc
Astellas Pharma Inc
AstraZeneca Plc
Astrogen Ltd
Atalanta Therapeutics Inc
Athira Pharma Inc
Atlantic Healthcare Plc
AUM LifeTech Inc
Autifony Therapeutics Ltd
Autotelic Bio Inc
Avicanna Inc
Axial Therapeutics Inc
Azymus Therapeutics Inc
B&A Therapeutics
BCWorld Pharm Co Ltd
Beech Tree Labs Inc
Beijing Toll Biotech Co Ltd
Belief Biomed Inc
Belrose Pharma Inc
BenevolentAI Ltd
Berg LLC
Better Life Pharmaceuticals Inc
Bial - Portela & Ca SA
Bio-Modeling Systems SAS
Bio-Pharm Solutions Co Ltd
BioArctic AB
Bioasis Technologies Inc
Biogen Inc
Bionaut Labs Inc
Biorchestra Co Ltd
BioVie Inc
Bisichem Co Ltd
Blackfynn Inc
Blue Therapeutics Inc
BlueRock Therapeutics LLC
Bopin (Shanghai) Biomedical Technology Co Ltd
BrainEver SAS
BrainStorm Cell Therapeutics Inc
Bristol-Myers Squibb Co
Britannia Pharmaceuticals Ltd
Bukwang Pharmaceutical Co Ltd
C4 Therapeutics Inc
C4X Discovery Holdings Plc
Calico Life Sciences LLC
Cantabio Pharmaceuticals Inc
Canvax Biotech SL
Caraway Therapeutics Inc
Carmot Therapeutics Inc
Carna Biosciences Inc
Casma Therapeutics Inc
Celavie Biosciences LLC
Celeris Therapeutics Inc
CellCure
Cellivery Therapeutics Inc
Celros Biotech Co Ltd
Cerecin Pte Ltd
CereSpir Inc
Cerevance Inc
Cerevel Therapeutics Holdings Inc
CHA Biotech Co Ltd
Chamishi Therapeutics Inc
Chase Therapeutics Corp
Chiesi Farmaceutici SpA
Chimerna Therapeutics Inc
CholesteniX Ltd
Chongqing Pharmaceutical Research Institute Co Ltd
Ci Therapeutics
Circadian Therapeutics
Clayton Biotechnologies Inc
Clene Inc
Clevexel Pharma SA
Clexio Biosciences Ltd
Coave Therapeutics
Cogentis Therapeutics Inc
Cognition Therapeutics Inc
Collaborative Medicinal Development LLC
Contera Pharma ApS
Convalesce Inc
Copernicus Therapeutics Inc
Corium Inc
Coya Therapeutics Inc
Creative Medical Technology Holdings Inc
Crossject SA
CuraSen Therapeutics Inc
Curemark LLC
CuroNZ Ltd
Cypralis Ltd
Dadang & BIO Co Ltd
DanPET AB
Deep Genomics Inc
DegenRx BV
Delpor Inc
Denali Therapeutics Inc
Denovo Biopharma LLC
DermaXon LLC
Diffusion Pharmaceuticals Inc
Dina Pharmaceuticals Inc
Dizlin Pharmaceuticals AB
DongKoo Bio & Pharma Co Ltd
DR.Noah Biotech Inc
E-scape Bio Inc
Easywell Biomedical Inc
EHL Bio Co Ltd
Eikonoklastes Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
EmendoBio Inc
Emerald Health Sciences Inc
Emyria Ltd
ENCEFA
Enveda Biosciences Inc
ES Therapeutics LLC
Evgen Pharma Plc
Exegenesis Bio Inc
Eyam Vaccines and Immunotherapeutics Ltd
F. Hoffmann-La Roche Ltd
FibroGenesis LLC
Forest Hills Partners Hong Kong Ltd
Fortuna Fix Inc
Fulcrum Therapeutics Inc
Gain Therapeutics Inc
GB Sciences Inc
Gene Therapy Research Institution Co Ltd
Generoath Co Ltd
Genervon Biopharmaceuticals LLC
GenKyoTex SA
Genmab AS
Gismo Therapeutics Inc
Glaceum Inc
Global BioLife Inc Ltd
GNT Pharma Co Ltd
GraySpace Therapeutics Inc
Grespo AB
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangzhou Dazhou Biomedical Technology Co Ltd
Guangzhou DM Intelligence Ltd
Guangzhou Henovcom Bioscience Co Ltd
Guangzhou Magpie Pharmaceutical Co Ltd
H. Lundbeck AS
Halia Therapeutics Inc
Hangzhou Zede Pharmaceutical Technology Co Ltd
Hebei Newtherapy BIo-Pharma Technology Co Ltd
Help Therapeutics
Herantis Pharma Plc
Herophilus
Hillhurst Biopharmaceuticals Inc
HLB Pharmaceutical Co Ltd
Hong Kong WD Pharmaceutical Co Ltd
Hope Biosciences LLC
Hopstem Biotechnology LLC
Ibex Biosciences LLC
Icagen Inc
ICB International Inc
iCELL Biotechnology Co Ltd
Icure Pharmaceutical Inc
Ildong Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co Ltd
Imago Pharmaceuticals Inc
Immune Modulation Inc
Immungenetics AG
Impel Pharmaceuticals Inc
Imstem Biotechnology Inc
Inexia Ltd
Inhibikase Therapeutics Inc
Innervace Inc
InnoMedica Holding AG
InnoPharmaScreen Inc
International Stem Cell Corp
Intra-Cellular Therapies Inc
Invisio Ltd
Io Therapeutics Inc
Ionis Pharmaceuticals Inc
Ipsen SA
iRegene Therapeutics Co Ltd
IRLAB Therapeutics AB
Jazz Pharmaceuticals Plc
Jeil Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Junaxo Inc
Kainos Medicine Inc
Kallyope Inc
Kariya Pharmaceuticals IVS
Kashiv BioSciences LLC
Keapstone Therapeutics Ltd
KeifeRx LLC
Kissei Pharmaceutical Co Ltd
Korea Pharma Co Ltd
Kyowa Kirin Co Ltd
Lan Sheng Biomedicine Suzhou Co Ltd
Lauren Sciences LLC
Lead Discovery Center GmbH
Lennham Pharmaceuticals Inc
LISCure Biosciences Co Ltd
Living Cell Technologies Ltd
Longevity Biotech Inc
Lucy Therapeutics Inc
Luye Pharma Group Ltd
Lys Therapeutics SAS
Lysogene SAS
MD Healthcare Inc
MegaNano BioTech Inc
MeiraGTx Holdings Plc
Mercaptor Discoveries Inc
Merck & Co Inc
Metabolic Solutions Development Company LLC
MetiMedi Pharmaceuticals Co Ltd
MimeTech Srl
Minerva Neurosciences Inc
Mission Therapeutics Ltd
Mitochon Pharmaceuticals Inc
Mitoconix Bio Ltd
MitoDys Therapeutics Ltd
MitoImmune Therapeutics Inc
Mitokinin LLC
Mitsubishi Tanabe Pharma Corp
Molomics Biotech SL
Montisera Ltd
Motac Neuroscience Ltd
MRM Health NV
MThera Pharma Co Ltd
Muna Therapeutics ApS
Myodopa Ltd
Nanomerics Ltd
Neonc Technologies Inc
Netherlands Translational Research Center BV
NeuExcell Therapeutics Inc
Neuracle Science Co Ltd
Neuraly Inc
Neuramedy Co Ltd
Neuren Pharmaceuticals Ltd
Neuro Vigor LLC
Neurochlore
Neurodon LLC
Neuroene Therapeutics LLC
Neuron23 Inc
Neurona Therapeutics Inc
NeuroNascent Inc
NeuroPn Therapeutics LLC
Neuropore Therapies Inc
NeuroSense Therapeutics Ltd
Neuvivo Inc
New Amsterdam Sciences Inc
New Biotic Inc
New World Laboratories Inc
Newron Pharmaceuticals SpA
Nexmos Inc
Nine Square Therapeutics Inc
Nitrase Therapeutics Inc
nLife Therapeutics SL
NLS Pharmaceutics AG
Nostrum Biodiscovery SL
Notitia Biotechnologies Co
Novartis AG
Novo Nordisk AS
NRG Therapeutics Ltd
NTZ Lab Ltd
Nuravax Inc
NurrOn Pharmaceuticals Inc
NutriBand Inc
NysnoBio LLC
OccamzRazor
Ohara Pharmaceutical Co Ltd
Omeros Corp
Oncodesign SA
Origami Therapeutics Inc
Orpheris Inc
Oryzon Genomics SA
Oxyrane Belgium NV
Parkure Ltd
Peptron Inc
Pfizer Inc
Pharma Two B Ltd
PharmaKure Ltd
PharmaTher Holdings Ltd
PharmatrophiX Inc
Pharmaxis Ltd
Phoenix Biotechnology Inc
Phoenix Life Sciences International Ltd
Pike Therapeutics Inc
PK Biosciences Corp
Plex Pharmaceuticals Inc
Polaryx Therapeutics Inc
PolyCore Therapeutics LLC
Praxis Precision Medicines Inc
Prazer Therapeutics
PRG S&Tech Inc
Priavoid GmbH
Prilenia Therapeutics Development Ltd
Primary Peptides Inc
Proclara Biosciences Inc
Progenra Inc
ProMIS Neurosciences Inc
Promius Pharma LLC
Prosetta Biosciences Inc
Prothena Corp Plc
Prous Institute for Biomedical Research SA
Psy Therapeutics Inc
PTC Therapeutics Inc
PureIMS BV
Quince Therapeutics Inc
Reata Pharmaceuticals Inc
reMYND NV
ReNeuron Group Plc
ResQ Biotech
Retrotope Inc
Revalesio Corp
Reven Holdings Inc
Reviva Pharmaceuticals Inc
Rionis
S.Biomedics Co Ltd
Sage Therapeutics Inc
Samus Therapeutics Inc
SanBio Co Ltd
Saniona AB
Sanofi
SciNeuro Pharmaceuticals
SeaBeLife Spas
Seelos Therapeutics, Inc.
Senda Biosciences Inc
Seneb BioSciences Inc
Sengenics Corp Pte Ltd
Serina Therapeutics Inc
Shanghai Green Valley Pharmaceutical Co Ltd
Shanghai Leado Pharmaceutical Technology Co Ltd
Shape Therapeutics Inc
Shenox Pharmaceuticals LLC
Shift Bioscience Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
SignPath Pharma Inc
Sihuan Pharmaceutical Holdings Group Ltd
Silo Pharma Inc
Silver Creek Pharmaceuticals Inc
Sinfonia Biotherapeutics Inc
Sinopia Biosciences Inc
SNLD Ltd
SOLA Biosciences LLC
SOM Biotech SL
Sorrento Therapeutics Inc
SparkBioPharma Inc
SQZ Biotechnologies Co
Stada Arzneimittel AG
Standigm Inc
STATegics Inc
Stealth BioTherapeutics Corp
Stellate Therapeutics Inc
Sumitomo Chemical Co Ltd
Sumitomo Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
Synapss Therapeutics Inc
Synaptogenix Inc
Synthonics Inc
Taho Pharmaceuticals Ltd
Taiwan Mitochondrion Applied Technology Co Ltd
Takeda Pharmaceutical Co Ltd
Tarus Therapeutics Inc
TauRx Therapeutics Ltd
Techfields Pharma Co Ltd
TechnoPhage SA
Teijin Pharma Ltd
Teikoku Pharma USA Inc
Tempero Bio
Tessara Therapeutics Pty Ltd
Teva Pharmaceutical Industries Ltd
The Greater Cannabis Company Inc
Therapeutic Solutions International Inc
Trailhead Biosystems Inc
Tranquis Therapeutics Inc
TreeFrog Therapeutics SAS
Treventis Corp
Triplet Therapeutics Inc
UCB SA
UniQure NV
Vanda Pharmaceuticals Inc
Vanqua Bio Inc
Varinel Inc
Vaxxinity Inc
Verge Genomics
Videns Incorp Ltd
Vimgreen Pharma Ltd
Vincere Biosciences Inc
Vitro Biopharma Inc
Vivifi Biotech Ltd
Vivozon Inc
Vivreon Biosciences LLC
Voyager Therapeutics Inc
Vyant Bio Inc
Whan In Pharm Co Ltd
Wren Therapeutics Ltd
XellSmart Biomedical (Shanghai) Co Ltd
Xoc Pharmaceuticals Inc
Yuhan Corp
Yumanity Therapeutics Inc
Zhittya Genesis Medicine Inc
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Parkinson’s Disease – Overview

Parkinson’s Disease – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Parkinson’s Disease – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Parkinson’s Disease – Companies Involved in Therapeutics Development

Parkinson’s Disease – Drug Profiles

Parkinson’s Disease – Dormant Projects

Parkinson’s Disease – Discontinued Products

Parkinson’s Disease – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Pharmaceuticals
New
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more